Climb Bio (CLYM)

The company’s lead programme is budoprutug, an anti-CD19 monoclonal antibody designed to target B cells. CD19 is widely expressed across B-cell development, making it a relevant target in diseases where B cells contribute to autoantibody production and immune dysfunction. Climb Bio is evaluating budoprutug for disorders including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, each of which involves immune system activity that can cause serious organ or blood-related complications.

Climb Bio’s pipeline also includes CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. APRIL is a cytokine involved in B-cell survival and antibody production, and it has become an important target of interest in kidney diseases linked to abnormal immunoglobulin activity. IgA nephropathy is a chronic kidney disorder that can progress to kidney failure in some patients, creating a need for disease-modifying therapies.

The company’s investment profile is typical of a development-stage biotech: value is tied to clinical trial progress, regulatory outcomes, safety data, funding capacity, and the competitive landscape in immunology and nephrology. Climb Bio stands out through its focus on targeted biologics for severe autoimmune and kidney-related diseases.